Clinical Trials · global
A Chance to Retain Infected Joint Implants: Anti-Biofilm Drug Trial Expands to the UK
Zaloganan will undergo randomized controlled testing during debridement surgery to determine whether local irrigation can reduce the risk of treatment failure within one year. Enrollment of the first UK patient advances this multinational trial of approximately 240 participants, but efficacy remains to be established by the results.
When an artificial knee joint becomes infected, patients may face more than a course of antibiotics: they may need further surgery or even removal of the implant. How to clear the infection while retaining the joint implant is the question Peptilogics’ investigational drug zaloganan seeks to answer. On November 5, the company announced that the Phase 2/3 RETAIN trial had enrolled its first UK patient, marking the study’s first enrollment outside the United States.
The patient enrolled through Leeds Teaching Hospitals and the UK National Institute for Health and Care Research (NIHR) Leeds Clinical Research Facility, with orthopedic surgeons Hemant Pandit and Jeya Palan leading the local study. According to the company’s announced plans, another 14 UK sites will participate; the overall study is expected to recruit approximately 240 participants at around 50 sites across the United States, the United Kingdom and Australia.
The study targets patients who develop a prosthetic joint infection after total knee replacement and undergo debridement, antibiotics and implant retention (DAIR). One reason these infections are difficult to eradicate is that bacteria can form biofilms on implant surfaces. This protective structure makes bacteria harder for antibiotics and the immune system to clear, creating a risk of recurrence when treatment seeks to retain the joint implant.
Zaloganan, also known as PLG0206, is an engineered antimicrobial peptide. According to Peptilogics, it is designed to disrupt bacterial cell membranes and target bacteria that persist within biofilms. The study uses local irrigation within the joint to deliver the drug, aiming to act at the infection site. Whether this mechanism translates into fewer treatment failures still requires confirmation in a controlled trial.
According to the company’s trial webpage, RETAIN uses a randomized, double-blind, placebo-controlled design. After debridement, patients receive a single administration of zaloganan or a matching placebo as the final step in a standardized irrigation procedure. Both groups then receive postoperative care according to hospital protocols, including any required antimicrobial treatment. The study will test whether adding the drug to existing treatment provides additional benefit.
The primary endpoint is treatment failure within 12 months, while a key secondary endpoint is surgery for prosthetic joint infection during the same period. The study will also monitor safety and record healthcare resource use, including length of hospital stay, readmissions and additional surgeries, to assess whether clinical improvement is accompanied by a reduction in the burden of care.
The early patient study currently supporting development was small and was not randomized or controlled. It is insufficient to establish efficacy, and its failure rate should not be directly compared with those of other studies. UK enrollment marks an expansion in the trial’s geographic reach and provides no new efficacy or safety results. Zaloganan remains an unapproved investigational drug. Whether it can help more patients retain their joint implants after infection control awaits an answer from this study with one year of follow-up.